Philips gets approval for new vent under emergency use authorization
By HME News Staff
Updated Wed April 15, 2020
AMSTERDAM - Royal Philips has introduced a ventilator, the Philips Respironics E30 ventilator, designed for large scale production. The vent can be used invasively or non-invasively, offering flexibility to adapt to treatment needs of patients with COVID-19, the company says. “The Philips Respironics E30 ventilator can deliver a range of treatment options, and we will quickly scale its production to 15,000 units per week in April,” said Frans van Houten, CEO of Royal Philips. On April 8, the U.S. Food and Drug Administration authorized the device for use in the U.S. during the COVID-19 public health emergency through its Emergency Use Authorization (EUA) process. Philips is working with the relevant regulatory authorities to also distribute the device globally. The company has started the production of the Philips Respironics E30 ventilator in its New Kensington site in western Pennsylvania, targeting a production of 15,000 per week in April. Philips, which previously announced plans to double the production of its hospital vents for May 2020 and achieve a four-fold increase by the third quarter, has invested several tens of millions of dollars in additional tools and molds, final assembly lines and test facilities, and has hired extra manufacturing employees and changed to 24/7 shifts.
Comments